Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate

European Journal of Haematology

Volumn 91, Issue 4, 2013, Pages 339-346

  Holien, Toril ^a   Olsen, Oddrun E ^a   Misund, Kristine ^a   Hella, Hanne ^a   Waage, Anders ^a,b   Rø, Torstein B ^a,b   Sundan, Anders ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Apoptosis; Artesunate; Diffuse large B cell lymphoma; Multiple myeloma; Therapy

Indexed keywords

ARTESUNATE; CASPASE 3; LIPOCORTIN 5; MYC PROTEIN; PROPIDIUM IODIDE; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IN VITRO STUDY; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MEASUREMENT; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; TIME; WESTERN BLOTTING;

APOPTOSIS; ARTESUNATE; DIFFUSE LARGE B-CELL LYMPHOMA; MULTIPLE MYELOMA; THERAPY;

ADENOSINE TRIPHOSPHATE; ANNEXIN A5; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARTEMISININS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; DRUG REPOSITIONING; GENE EXPRESSION REGULATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MESENCHYMAL STROMAL CELLS; MULTIPLE MYELOMA; PRIMARY CELL CULTURE; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84884818481     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12176     Document Type: Article

References (26)

1. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 2012;9:135-43.
2. Tilly H, Vitolo U, Walewski J, da Silva MG, Shpilberg O, Andre M, Pfreundschuh M, Dreyling M. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii78-82.
3. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
4. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-26.
5. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, Mulligan G, Chesi M, Bergsagel PL, Fonseca R. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011;25:1026-35.
6. Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013;121:2253-63.
7. Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med 2011;17:1217-20.
8. World Health Organization. Guidelines for the Treatment of Malaria. Geneva, Switzerland: WHO press, 2006.
9. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol 2001;18:767-73.
10. Efferth T, Sauerbrey A, Olbrich A, et al. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 2003;64:382-94.
11. Efferth T, Briehl MM, Tome ME. Role of antioxidant genes for the activity of artesunate against tumor cells. Int J Oncol 2003;23:1231-5.
12. Holien T, Vatsveen TK, Hella H, et al. Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. Leukemia 2012;26:1073-80.
13. Holien T, Vatsveen TK, Hella H, Waage A, Sundan A. Addiction to c-MYC in multiple myeloma. Blood 2012;120:2450-3.
14. Vindelov LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-7.
15. Misund K, Baranowska KA, Holien T, Rampa C, Klein DC, Borset M, Waage A, Sundan A. A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells. J Biomol Screen 2013;18:637-46.
16. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, Anderson KC. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003;63:6174-7.
17. Li S, Xue F, Cheng Z, Yang X, Wang S, Geng F, Pan L. Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFkappaB p65. Int J Hematol 2009;90:513-21.
18. Sieber S, Gdynia G, Roth W, Bonavida B, Efferth T. Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate. Int J Oncol 2009;35:149-58.
19. Chen H, Shi L, Yang X, Li S, Guo X, Pan L. Artesunate inhibiting angiogenesis induced by human myeloma RPMI8226 cells. Int J Hematol 2010;92:587-97.
20. Lu JJ, Meng LH, Shankavaram UT, Zhu CH, Tong LJ, Chen G, Lin LP, Weinstein JN, Ding J. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol 2010;80:22-30.
21. Davis TM, Phuong HL, Ilett KF, Hung NC, Batty KT, Phuong VD, Powell SM, Thien HV, Binh TQ. Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria. Antimicrob Agents Chemother 2001;45:181-6.
22. Miller RS, Li Q, Cantilena LR, Leary KJ, Saviolakis GA, Melendez V, Smith B, Weina PJ. Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: phase 1b study. Malar J 2012;11:255.
23. Krishna S, Uhlemann AC, Haynes RK. Artemisinins: mechanisms of action and potential for resistance. Drug Resist Updat 2004;7:233-44.
24. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3460-7.
25. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3452-9.
26. Handrick R, Ontikatze T, Bauer KD, Freier F, Rubel A, Durig J, Belka C, Jendrossek V. Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway. Mol Cancer Ther 2010;9:2497-510.